CHRNA7 and Parkinson disease: In fact, recent studies indicate that partial and full agonists of α7 nAChRs are effective in the treatment of neurological disorders such as schizophrenia and Parkinson’s disease and also in the control of drug-induced motor disorders, such as levodopa-induced dyskinesias which arises during the course of Parkinson’s disease treatment [6,7,8,9,10].